ArticleDiscover oncology2026
Polo-like kinase 5 is lowly expressed and negatively correlates with poorer differentiation, and its positivity may predict a better prognosis in patients with colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe Polo-like kinase (PLK) family contains five members, among which the former (PLK1-4) has prognostic value in colorectal cancer (CRC); however, since PLK5 was recently discovered, its related information is scarce. This study aimed to investigate the expression of PLK5 in CRC tissues versus adjacent nontumor tissues and its correlation with the characteristics and prognosis of CRC patients.
methodsPLK5 expression was detected in 107 CRC tissues and 20 adjacent nontumor tissues via immunohistochemistry. CRC patient characteristics, relapse-free survival (RFS), and overall survival (OS) information were acquired. The Human Protein Atlas database was used for verification of the correlation of PLK5 with OS.
resultsPLK5 expression was lower in CRC tissues than in adjacent nontumor tissues (P < 0.001); specifically, 15.0% of patients had positive PLK5 expression in tumors, and 4.7% of patients had high PLK5 expression in tumors. PLK5 expression was negatively correlated with poorly differentiated or undifferentiated tumors (r=-0.312, P = 0.001) but not with other patient characteristics. RFS tended to be greater in the PLK5-positive group than in the PLK5-negative expression group (P = 0.077) and in the PLK5-high-expression group than in the PLK5-low-expression group (P = 0.167), but the difference did not reach statistical significance. OS revealed similar trends (P = 0.220 and P = 0.264). The Human Protein Atlas database revealed that high PLK5 expression was correlated with longer OS in the rectum adenocarcinoma (TCGA) cohort (P = 0.037) and tended to be associated with better OS in the colon adenocarcinoma (validation) cohort (P = 0.120) and the rectum adenocarcinoma (validation) cohort (P = 0.150).
conclusionPLK5 is a potential tumor-suppressor biomarker for CRC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.